By Mike Stobbe

Health care workers and nursing home residents should be at the front of the line when the first coronavirus vaccine shots become available, an influential government advisory panel said in Tuesday.

The Advisory Committee on Immunization Practices voted 13-1 to recommend priority be given to those groups in the first days of any coming vaccination program, when doses are expected to be very limited.

The two priority groups encompass around 24 million Americans out of a U.S. population of about 330 million.

THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below.

NEW YORK (AP) — An influential government advisory panel convened on Tuesday to answer one of the most pressing questions in the U.S. coronavirus outbreak: Who should be at the front of the line when the first vaccine shots become available?

The Advisory Committee on Immunization Practices was scheduled to vote on a proposal that would give priority to health care workers and nursing home patients.

The two groups encompass around 23 million Americans out of a U.S. population of about 330 million.

As the virtual meeting got underway, panel member Dr. Beth Bell of the University of Washington noted that on average, one person is dying of COVID-19 per minute in the U.S. right now, “so I guess we are acting none too soon.”

Later this month, the Food and Drug Administration will consider authorizing emergency use of two vaccines made by Pfizer and Moderna. Current estimates project that no more than 20 million doses of each vaccine will be available by the end of 2020. And each product requires two doses.

As a result, the shots will be rationed in the early stages.

The advisory panel will meet again at some point to decide who should be next in line. Among the possibilities: teachers, police, firefighters and workers in other essential fields such as food production and transportation; the elderly; and people with underlying medical conditions.

Experts say the vaccine will probably not become widely available in the U.S. until the spring.

The 15-member panel of outside scientific experts, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention, who almost always approves them.

The recommendations are not binding, but for decades they have been widely heeded by doctors, and they have determined the scope and funding of U.S. vaccination programs.

It will be up to state authorities whether to follow the guidance. It will also be left to them to make further, more detailed decisions if necessary — for example, whether to put emergency room doctors and nurses ahead of other health care workers if vaccine supplies are low.

The outbreak in the U.S. has killed nearly 270,000 people and caused more than 13.5 million confirmed infections, with deaths, hospitalizations and cases rocketing in recent weeks.

About 2 million people are living in nursing homes and other U.S. long-term care facilities. Those patients and the staff members who care for them have accounted for 6% of the nation’s coronavirus cases and a staggering 39% of the deaths, CDC officials say.

The number of health care workers covered by the panel's recommendation would be about 21 million.

That's a broad category that includes medical staff who care for — or come in contact with — patients in hospitals, nursing homes, clinics and doctor’s offices. It also includes home health care workers and paramedics. Depending on how state officials apply the panel's recommendations, it could also encompass janitorial staff, food service employees and medical records clerks.

The government estimates people working in health care account for 12% of U.S. COVID-19 cases but only about 0.5% of deaths. Experts say it’s imperative to keep health care workers on their feet so that they can administer the shots and tend to the booming number of infected Americans.

For months, members of the immunization panel had said they wouldn't take a vote until the FDA approved a vaccine. That is customary procedure for the panel, with some exceptions, such as during a flu outbreak in 2009. But late last week, the group suddenly scheduled an emergency meeting for Tuesday.

The panel's chairman, Dr. Jose Romero, said the decision stemmed from a realization that the states are facing a Friday deadline to place initial orders for the Pfizer vaccine and determine where they should be delivered. The committee decided to meet now to give state and local officials guidance, he said.

But some panel members and other experts had also grown concerned by comments from Trump administration officials that suggested differing vaccine priorities.

Dr. Deborah Birx of the White House coronavirus task force said in a meeting with CDC officials last month that people 65 and older should go to the head of the line, according to a federal official who was not authorized to discuss the matter and spoke to The Associated Press on condition of anonymity.

Then last week U.S. Health and Human Services Secretary Alex Azar stressed that ultimately governors will decide who in their states gets the shots. Vice President Mike Pence echoed that view.

The comments churned up long-standing concerns during the Trump administration that vaccination decisions would be dictated by political concerns instead of science.

Asked whether Azar's comment played a role in the scheduling of the meeting, Romero said; “We don’t live in a bubble. We know what he said. But that wasn’t the primary reason this is being done.”

Jason Schwartz, a professor of health policy at the Yale School of Public Health, said it makes sense for the panel to take the unusual step of getting its recommendation out first.

“Without that formal recommendation, it does create a void from which states could go off in all sorts of different directions,” said Schwartz, who is not on the panel.

HHS officials have said they will distribute initial doses to states based on population, and it's possible some states won't receive enough to cover all of their health care workers and nursing home residents.

As a result, governors may have to decide which health care workers or which regions get shots first, Schwartz said.

“It's up to states to figure out the more granular detail,” he said.

Updated on December 1, 2020, at 5:54 p.m. ET with the latest information.

Share:
More In Politics
Nike, AMEX Among Companies Sticking to Pledge to Not Fund January 6 Objectors
Following the attack on the Capitol last year, several major corporations promised to no longer pour funds into the campaigns of Republican lawmakers who supported the January 6 insurrection. But not all have stood firm on their word. Among those that did keep to their promise were Nike, American Express, and Walgreens.
N.H. Rep Reflects on 'Thousand Acts of Courage' That Saved Democracy on Jan. 6
Rep. Annie Kuster (D-N.H. 2nd District) joined Cheddar's "Between Bells" to reflect on the January 6 insurrection and her personal experience in the Capitol when rioters attempted to overtake the House chamber. "What I now understand to be true is that the mob of rioters had reached the third floor and was literally in the hallway running toward us as we ducked into the elevator," she told Cheddar. Kuster recalled the fear she felt, wondering what might have happened if the insurrectionists crossed paths with her group. Kuster noted that she has since received therapy to help cope with the traumatic event. "A thousand acts of courage saved our life and saved our democracy," she said.
How January 6 Insurrection Could Impact Midterm Elections, 2024 Presidential Race
Andy Kroll, Washington bureau chief at Rolling Stone, joined Cheddar's Baker Machado to discuss the anniversary of the January 6 insurrection and how it could impact upcoming elections. Kroll talked about whether or not Trump's influence will aid Republicans in the midterms and how it could be a setup for the former president to run in the 2024 presidential election. "This day has become really almost a kind of cause for Republican base voters," he said. "And you're going to see that fueling some turnout, you're going to see that fueling, even, candidates running for office in these midterm elections."
ProPublica/WSJ: New Report Reveals Facebook's Role In Jan. 6 Capitol Riot
According to a recent analysis from ProPublica and the Wall Street Journal an analysis of Facebook posts, internal company documents, and interviews reveal key evidence about the social media giant's role in January 6 insurrection. National Reporter at ProPublica Craig Silverman, joined Cheddar to discuss more.
AT&T, Verizon Agree to Delay 5G Rollout After Airlines Raise Safety Concerns
AT&T and Verizon have agreed to delay activating their 5G services for two weeks after Airlines for America, a lobbying group that represents American, Delta, and other airlines, filed a petition last week with the FCC to stop the deployment of 5G in the U.S. over concerns that the network can interfere with certain systems on airplanes. President Biden spoke out about it, saying it would avoid further delays and cancellations of flights. Light Reading 5G and Mobile Strategies Director Mike Dano joined Cheddar News' Closing Bell to discuss.
Stocks Close Lower as Investors Digest Fed Minutes
On a day where the Dow and Russell 2000 each closed more than 3% lower, Melissa Armo, founder and owner of The Stock Swoosh, says Wednesday's big sell-off could extend into after-hours trading. She joined Cheddar News' Closing Bell for more.
2022 Marks Crucial Year for Big Tech With Midterm Elections Looming
The new year has just gotten underway, but the clock is already ticking for the Democratic-led Congress to pass bills regulating big tech. Evan Greer, Director for Fight For the Future, joins Cheddar News to explain why Democratic lawmakers would want to push legislation now, and what a Republican takeover would mean for the industry.
Walmart, Kroger Raise At-Home COVID-19 Test Prices
Americans looking to purchase at-home COVID-19 tests will now have to shell out a bit more money after an agreement expired between the White House and companies to sell the tests at cost. The price of Abbot's BinaxNow test kit from October to December was $14 apiece; on Tuesday, Walmart's website listed the test for $19.88, and Kroger listed the tests for $23.99. Carbon Health Regional Clinical Director Dr. Bayo Curry-Winchell joined Cheddar News' Closing Bell to discuss the impact higher prices will have as the nation experiences another surge in cases.
Load More